BAT Korea Subsidiary Launches "Neo Fresco" E-Cigarette Stick in Mint

BAT by 2FIRSTS.ai
Jul.26.2024
BAT Korea Subsidiary Launches "Neo Fresco" E-Cigarette Stick in Mint
BAT's Korean subsidiary launches new e-cigarette "Neo Fresco" with mint packaging in convenience stores for 4,800 Korean won.

According to a report by M-I.KR on July 26th, British American Tobacco (BAT) announced that its South Korean subsidiary will be launching the "Glo Hyper" series of e-cigarette-specific cigarette sticks called "Neo Fresco." The packaging design of "Neo Fresco" features a mint color. This new product will be available for sale at convenience stores and tobacco retailers nationwide, priced at 4,800 Korean won ($3.47). With the launch of this new product, the Glo Hyper series' lineup of "Neo" cigarette sticks has now expanded to a total of 10 varieties.


We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

Small ENDS Manufacturers Press FDA on Abuse Liability Standards as Agency Defines Pharmacological Review Framework
Small ENDS Manufacturers Press FDA on Abuse Liability Standards as Agency Defines Pharmacological Review Framework
At the third session of its PMTA roundtable, the FDA outlined its framework for assessing abuse liability in ENDS products, emphasizing the role of nicotine pharmacokinetics and product-specific data in APPH determinations. Small manufacturers questioned the high cost of clinical PK studies and the absence of defined numeric thresholds, while raising bridging strategies and PBPK modeling as potential alternatives.
Feb.11
BAT CEO Says 2026 Return to Growth Hinges on U.S. Enforcement, Highlights Oral Leadership
BAT CEO Says 2026 Return to Growth Hinges on U.S. Enforcement, Highlights Oral Leadership
British American Tobacco said 2026 will mark a return to its mid-term growth algorithm, but CEO Tadeu Marroco stressed that deliverywill depend heavily on enforcement against illicit vapour products in the United States. Speaking at the FY2025 results call, he positioned Modern Oral as the company’s primary structural growth engine, reframed accelerating cigarette declines through “poly-usage,” and reinforced capital discipline with an expanded share buyback plan.
Feb.12
KT&G Q4 and Full-Year 2025 Results: Global CC Strongest, NGP Penetration Expands
KT&G Q4 and Full-Year 2025 Results: Global CC Strongest, NGP Penetration Expands
According to KT&G’s official website (Feb 5, 2026), KT&G released its 2025 fourth-quarter and full-year results. Driven by strong growth in its overseas cigarette business and a rebound in its real estate business, the company posted double-digit increases in both revenue and operating profit, reaching record-high performance.
Feb.05 by 2FIRSTS.ai
Product | Claiming “U.S.-Made E-Liquid” and “80,000 Puffs,” VOOPOO Launches NAVI×Cyph 80K
Product | Claiming “U.S.-Made E-Liquid” and “80,000 Puffs,” VOOPOO Launches NAVI×Cyph 80K
VOOPOO’s website shows the company has introduced the NAVI×Cyph Kit 80K, an open-system, refillable vaping kit claimed to deliver up to 80,000 puffs. The device features a 1,500mAh battery with USB Type-C charging and comes in 12 flavors. A promotional image posted on VOOPOO’s official Instagram account includes the phrase “E-LIQUID BUILT IN THE USA.”
Feb.10 by 2FIRSTS.ai
BAT rolls out VELO nicotine pouches in Argentina as social media buzzes about ZYN distribution
BAT rolls out VELO nicotine pouches in Argentina as social media buzzes about ZYN distribution
BAT Argentina says it has launched VELO nicotine pouches in Argentina, positioning the product as an adult alternative that contains no tobacco and involves no combustion. At the same time, social media discussion and media reporting indicate that Philip Morris International’s ZYN nicotine pouches are also being distributed through Argentine channels.
Jan.12 by 2FIRSTS.ai
Research Summary | NHANES Study: Smoking or E-Cigarette Use Linked to Higher Prevalence of Elevated Blood Pressure and Hypertension
Research Summary | NHANES Study: Smoking or E-Cigarette Use Linked to Higher Prevalence of Elevated Blood Pressure and Hypertension
A cross-sectional analysis based on the US NHANES 2021–2023 cycle, including 6,262 participants aged over 12, found that compared with people who neither smoke nor vape, those who smoke and/or use e-cigarettes had a higher prevalence of elevated blood pressure and hypertension. After full adjustment, smoking/vaping was associated with elevated blood pressure (aOR 1.34) and hypertension (aOR 1.46), and with a 1.05 mmHg higher diastolic blood pressure.
Feb.09 by 2FIRSTS.ai